Par Drugs And Stock Retained Earnings
| PAR Stock | 290.40 11.35 4.07% |
Par Drugs And fundamentals help investors to digest information that contributes to Par Drugs' financial success or failures. It also enables traders to predict the movement of Par Stock. The fundamental analysis module provides a way to measure Par Drugs' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Par Drugs stock.
| Last Reported | Projected for Next Year | ||
| Retained Earnings | 625.5 M | 656.8 M |
Par | Retained Earnings |
Par Drugs And Company Retained Earnings Analysis
Par Drugs' Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current Par Drugs Retained Earnings | 625.51 M |
Most of Par Drugs' fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Par Drugs And is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
| Competition |
Based on the latest financial disclosure, Par Drugs And has a Retained Earnings of 625.51 M. This is 32.84% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The retained earnings for all India stocks is 93.3% higher than that of the company.
Par Retained Earnings Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Par Drugs' direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Par Drugs could also be used in its relative valuation, which is a method of valuing Par Drugs by comparing valuation metrics of similar companies.Par Drugs is currently under evaluation in retained earnings category among its peers.
Par Fundamentals
| Return On Equity | 0.21 | ||||
| Return On Asset | 0.14 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.30 % | ||||
| Current Valuation | 3.39 B | ||||
| Shares Outstanding | 12.3 M | ||||
| Price To Book | 3.69 X | ||||
| Price To Sales | 3.43 X | ||||
| Revenue | 956.4 M | ||||
| Gross Profit | 457.57 M | ||||
| EBITDA | 229.53 M | ||||
| Net Income | 145.01 M | ||||
| Total Debt | 159.79 M | ||||
| Book Value Per Share | 78.69 X | ||||
| Cash Flow From Operations | 202.49 M | ||||
| Earnings Per Share | 14.84 X | ||||
| Number Of Employees | 122 | ||||
| Beta | 0.15 | ||||
| Market Capitalization | 3.57 B | ||||
| Total Asset | 1.02 B | ||||
| Retained Earnings | 625.51 M | ||||
| Working Capital | 471.85 M | ||||
| Net Asset | 1.02 B |
About Par Drugs Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Par Drugs And's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Par Drugs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Par Drugs And based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Par Stock
Par Drugs financial ratios help investors to determine whether Par Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Par with respect to the benefits of owning Par Drugs security.